In the subcutaneous xenograft model, despite beginning with similar average tumor sizes between 0 and 3 days after the TMZ treatment, the 3KR expressing gliomas showed marked decreases in size similar to controls (mice receiving cells that expressed GFP); however, the WT Olig2-expressing gliomas maintained their tumor size to a large extend (Fig. 3f). This evidence concerns the gene OLIG2 and glioma.